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ABSTRACT
The success rate of catheter ablation in atrial fibrillation (AF) is known to be lower 
in females than in males. However, while the exact mechanism for this phenomenon 
remains to be elucidated, tissue fibrosis may play an important role in this regard. It 
has been shown that fibrosis promotes AF and its recurrence, thereby substantially 
reducing the efficacy of catheter ablation in AF patients. Thus, we hypothesized that 
fibrosis may contribute to gender differences in the outcomes of AF catheter ablation. 
Here we systematically assessed pulmonary vein sleeves obtained from 166 
patients with and without long-standing persistent-AF (LSP-AF) in order to identify 
gender-specific mechanistic differences in fibrosis remodeling of AF patients.
Histological analysis revealed that the female LSP-AF group, rather than its male 
counterpart, had a higher degree of fibrosis when compared to the NON-AF group. 
Further analysis using microarray, immunohistochemistry and Western Blot displayed 
that gender differences in fibrosis remodeling of LSP-AF were mainly due to the 
inherent differential expression of fibrosis-related genes (n=32) and proteins (n=6). 
Especially, those related to the TGFβ/Smad3 pathway appeared to be up-regulated 
in the female LSP-AF group thus promoting an aggravation of fibrosis remodeling. 
In summary, our data suggest that the aggravation of fibrosis remodeling in women 
may be an important reason for the low success rate of AF catheter ablation when 
compared to men. Therefore, inhibiting the TGFβ/Smad3 pathway-mediated fibrosis 
could represent an interesting target for future therapeutic concepts to improve the 
success rate of AF catheter ablation in women.
INTRODUCTION
Atrial fibrillation (AF) is one of the most prevalent 
arrhythmias worldwide and it is related to an increased 
cardiovascular morbidity and mortality [1]. However, so 
far, gender-specific differences in AF patients are widely 
neglected, and substantial knowledge gaps do exist in 
the understanding of epidemiology, pathophysiology, 
presentation, and prognosis between men and women [2]. 
Recent studies have suggested that the incidence, 
clinical presentation and consequences of AF are different 
between genders. For instance, while men are found to 
have a 1.5-fold higher risk of developing AF than women, 
but this gap appears to become balanced with advancing 
age due to the longer life-span of women [3]. In contrast, 
more comorbidities such as heart failure or stroke are 
usually found in women [4]. 
With regards to the treatment of AF patients, 
catheter-ablation represents a reasonable therapy strategy 
for both genders. However, interestingly, women are more 
likely to experience higher frequency of recurrence when 
compared to men [5]. While the exact mechanism for 
this phenomenon remains to be elucidated, fibrosis has 
been suggested to play a key role in this regard. Fibrosis 
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remodeling leads to a dissociation in atrial conduction and 
thereby promotes AF which then ultimately results in a 
lower efficacy of ablation therapy. [6]. Next, it has been 
suggested that the more extensive the fibrosis is, the more 
ineffective the ablation therapy becomes [7].
Therefore, we hypothesized that fibrosis may play an 
important role in the less effective AF ablation outcomes 
in women when compared to men. Subsequently, in the 
present study we comprehensively assessed pulmonary 
vein sleeves obtained from 166 patients with and without 
long-standing persistent-AF (LSP-AF) in order to identify 
gender-specific mechanistic differences in fibrosis 
remodeling of AF patients.
RESULTS
Patients characteristics
Patient characteristics were summarized in Table 
1 and Supplementary Table 1. In regard to the gender 
comparison there were no differences between women 
and men for in left atrial enlargement ratio, age and 
hypertension (Supplementary Table 1). Comparison in 
regard to AF and NON-AF also displayed no significant 
gender differences in regard to age, clinical diagnosis, 
accompanying disease and echocardiographic parameters 
(Table 1).
Figure 1: Gender difference in collagen volume fraction (CVF) (X60, bar = 50 um). Female group: NON-AF, n = 30(blue solid 
circle); LSP-AF, n = 55(red solid diamond); Male group: NON-AF, n = 35(blue hollow circle); LSP-AF, n = 46(red hollow diamond). A. 
and B., Masson staining of pulmonary vein sleeves from female NON-AF and LSP-AF group. C. and D., Masson trichrome of pulmonary 
vein sleeves from male NON-AF and LSP-AF group. Collagen (blue), Cardiac muscle (red), Nuclei (black). E., Comparative analysis of 
CVF in Female group between NON-AF and LSP-AF group. P ** < 0.01; Comparative analysis of CVF in Male group between NON-AF 
group and LSP-AF group. PNS > 0.05.Y axis, CVF (100%) = collagen area/total area. LSP-AF, long-standing-persistent AF. All data are 
expressed as means ± SEM. Unpaired t-test.
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Collagen volume fraction (CVF) 
To assess the degree of fibrosis remodeling, CVF 
was assessed in representative sections from each group 
by Masson’s trichrome staining and shown in Figure 
1A-1D. CVF was significantly increased (Figure1E, P = 
0.0019 < 0.01) in the female LSP-AF group (Figure 1B, 
CVF = 29.83% ±11.22%) when compared to the female 
NON-AF group (Figure 1A, CVF = 20.82%± 14.27%). 
In contrast, it did not differ significantly (Figure 1E, P= 
0.7196) between the male LSP-AF group (Figure 1D, 
CVF = 22.73% ±10.42%) and the corresponding NON-
AF male group (Figure 1C, CVF = 21.90% ±10.20%). 
These findings suggested, an aggravation of fibrosis 
remodeling in the female LSP-AF group but not in its 
male counterpart. Further analysis revealed there was a 
positive correlation between fibrosis remodeling and LSP-
AF in females (Pearson r = 0.3319, P < 0.01), but not in 
males (Pearson r = 0.04050, P = 0.7196) (Supplemental 
Table 2).
Receiver operating characteristic (ROC) curve 
analysis
Next, ROC curve analysis was performed to 
evaluate the utility of CVF in male and female subjects to 
predict the occurrence of LSP-AF (Figure2). The results 
revealed statistical significance in females with an optimal 
cut-off value for female CVF to predict the presence of 
LSP-AF of was > 16.72%, with 56.7% specificity and 
83.6% sensitivity (AUC = 0.7, 95% CI: 0.591-0.795, P < 
0.01), while there was no statistical significance in male 
CVF to predict the presence of LSP-AF (AUC = 0.508, 
95% CI: 0.395-0.621, P = 0.902). Thus, when compared 
Table 1: Clinical characteristics of study population
Classification
Female
P-value
Male
P-valueNON-AF 
(n=30)
LSP-AF
(n=55)
NON-AF
(n=35)
LSP-AF
(n=46)
Age, y 58.9±6.1 57.7±6.0 0.38 56.6±5.4 57.0±5.3 0.75
Clinical diagnosis (n%)
MS+MR 15(50%) 39(70.91%) 0.06 5(14.29%) 15(32.61%) 0.06
MR 14(46.67%) 15(27.27%) 0.07 29(82.86%) 30(65.22%) 0.08
MS 1(3.33%) 1(1.82%) 0.66 1(2.86%) 1(2.17%) 0.84
Accompanied disease (n%)
AVD 9(30%) 20(36.36%) 0.55 14(40%) 14(30.43%) 0.37
TVD 4(13.33%) 18(32.73%) 0.05 7(20%) 18(39.13%) 0.06
CHF 0(0%) 2(3.64%) 0.29 0 (0%) 0(0%)
CHD 7(23.33%) 21(38.18%) 0.16 8(22.86%) 15(32.61%) 0.34
Cerebral infarction 4(13.33%) 8(14.55%) 0.89 2(5.71%) 1(2.17%) 0.40
Left atrial thrombus 0(0%) 6(10.91%) 0.06 8(22.86%) 4(8.70%) 0.08
Pulmonary hypertension 3(10%) 5(9.09%) 0.89 6(17.14%) 12(26.09%) 0.34
Hyperthyroidism 2(6.67%) 0(0%) 0.05 1(2.86%) 1(2.17%) 0.84
Gout 0(0%) 0(0%) 0(0%) 1(2.17%) 0.38
Hypertension
I 0(0%) 1(1.82%) 0.46 0(0%) 1(2.17%) 0.38
II 1(3.33%) 1(1.82%) 0.66 4(11.43%) 2(4.35%) 0.23
III 6(20%) 10(18.18%) 0.84 6(17.14%) 6(13.04%) 0.61
Echocardiography
LAD(mm) 48.47±5.95 48.22±5.35
0.84
49.66±5.21 51.78±5.02
0.07
LAER 1.28±0.16 1.27±0.14 1.24±0.13 1.30±0.13
LVEF 0.59±0.09 0.58±0.07 0.80 0.57±0.06 0.57±0.06 0.95
LVFS 0.28±0.04 0.28±0.04 0.60 0.29±0.05 0.28±0.04 0.46
LVEDD(mm) 52.10±5.28 49.69±5.73 0.06 56.44±6.35 54.22±6.16 0.12
Data is presented as means±SEM. LSP-AF, long standing persistent atrial fibrillation; MS, mitral stenosis; MR, mitral 
regurgitation; AVD, Aortic valve disease; TVD, tricuspid valve disease; CHF, congestive heart failure ;CHD, coronary heart 
disease; LAD, left atrial diameter; LAER, left atrial enlargement ratio: female, LAD/38;male, LAD/40; LVEF, left  ventricular 
ejection  fraction;  LVFS, left ventricular fractional shortening; LVEDD, left ventricular end diastolic dimension; P-value 
(female: NON-AF vs LSP-AF; male: NON-AF vs LSP-AF).
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Figure 3: Gender differences in dysregulated AF-related genes. A. and B., The hierarchical cluster analysis of differentially 
expressed mRNAs associated with LSP-AF between female group and male group (n = 3/group). The relative gene log2 expression 
changes are expressed by a color gradient intensity scale, as shown in the top left corner. Green color indicates down-regulation, and red 
color indicates up-regulation of mRNA expression. Each row represents a separate sample and each column represents a single mRNA. 
Comparative analysis of dysregulated Total mRNA C., up-regulated mRNA D., and down-regulated mRNA E. in LSP-AF group between 
female and male group. Pink, Female-specific part; Purple, overlapping part, Blue, Male-specific part.
Figure 2: Gender difference in CVF to predict the presence of LSP-AF. Female group: NON-AF, n = 30; LSP-AF, n = 55; Male 
group: NON-AF, n = 35; LSP-AF, n = 46; A. and B., Receiver operating characteristic (ROC) curves of gender difference in CVF to predict 
the presence of LSP-AF. AUC indicates area under ROC curve.
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with male CVF, the female CVF showed good predictive 
values for the presence of LSP-AF. 
Dysregulated mRNA expression profiles in LSP-
AF
Microarray was performed to assess for gender 
differences in dysregulated mRNA expression profiles 
in patients with LSP-AF and results showed systematic 
variations between females and males respectively (Figure 
3A and 3B). In the female LSP-AF group, a total of 516 
differentially expressed mRNAs (316 upregulated, 200 
downregulated) (Supplemental Table 3) were found, 
while in the male LSP-AF group, 417 differentially 
expressed mRNAs were detected (215 upregulated, 202 
downregulated) were found (Supplemental Table 4). 
Further analysis revealed that in the LSP-AF groups, 
only 57 mRNAs (35 upregulated, 22 downregulated) 
were overlapping between genders (Figure 3C) 
(Supplemental Table 6), while most mRNAs appeared 
to be gender-specific with 459 female-specific mRNAs 
(281 upregulated, 178 downregulated) (Supplemental 
Table 5) and 360 male-specific mRNAs (180 upregulated, 
Figure 4: Gender differences in categories of AF-related genes. A., Comparative analysis of GO categories of AF-related genes 
between female LSP-AF and male LSP-AF group. B., Comparative analysis of Pathway categories of AF-related genes in LSP-AF group 
between female group and male group. Pink, Female-specific part; Purple, overlapping part, Blue, Male-specific part. C., GO categories of 
AF-related genes (Top5): Female-specific categories (red bar): immune response; inflammatory response; blood coagulation; Overlapping 
categories (red and blue bar): small molecule metabolic process; cell adhesion; male-specific categories (blue bar): respiratory electron 
transport chain; extracellular matrix (ECM) organization; Signal transduction. Y axis, -log
10
P-value;X axis, GO categories of AF-related genes; 
D., Pathway categories of AF-related genes (Top5):Female-specific categories (red bar):Focal adhesion; PI3K-Akt signaling pathway 
;Malaria ;Staphylococcus aureus infection ; Overlapping categories (red bar and blue): Metabolic pathways; Male-specific categories (blue 
bar): Huntington’s disease; Parkinson’s disease; Alzheimer’s disease; Oxidative phosphorylation. Y axis, --log
10
P-value; X axis, Pathway 
categories of AF-related genes.
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180 downregulated) (Figure 3D and 3E) (Supplemental 
Table 7) suggesting that there were substantial gender 
differences in dysregulated mRNA expression profiles in 
patients with LSP-AF.
Categories of AF-related genes by GO and 
pathway analysis 
Gene ontology (GO) analysis is the key functional 
classification method used at NCBI and can organize 
genes into hierarchical categories and uncover gene 
regulatory networks on the basis of biological processes 
and molecular functions. Pathway Analysis is used to 
identify canonical pathways representing genes. In a 
further step, GO and Pathway analysis were applied to 
classify differentially expressed AF related mRNAs.
Gender differences are displayed in categories 
of AF-related gene (Figure 4A and 4B) 
(Supplemental Table 8-11)
• female-specific: GO, 183(Supplemental Figure 
1); Pathway 31(Supplemental Figure 2) 
• overlapping: GO, 178(Supplemental Figure 3); 
Pathway, 98(Supplemental Figure 4) 
• male-specific: GO, 200(Supplemental Figure 
5); Pathway 34(Supplemental Figure 6)
Representative top5 categories of AF-related gene 
are shown as follows: 
GO analysis: (Figure 4C)
• female-specific group: immune response; 
inflammatory response; blood coagulation
• overlapping group: small molecule metabolic 
process; cell adhesion
• male-specific group: respiratory electron 
transport chain; extracellular matrix (ECM) 
organization; Signal transduction
Pathway analysis (Figure 4D)
• female-specific group: Focal adhesion; 
PI3K-Akt signaling pathway; Malaria; 
Staphylococcus aureus infection
• overlapping group: Metabolic pathways
male-specific group: Huntington’s disease; 
Parkinson’s disease; Alzheimer’s disease; Oxidative 
phosphorylation. 
In summary we found that the most obvious 
category for both genders was metabolism-related 
suggesting that those categories may play an important 
regulatory role in AF (Figure 4C and 4D).
Categories of fibrosis remodeling related genes in 
LSP-AF
The precise mechanisms and signaling pathways 
involved in the development of atrial fibrosis in AF 
remain to be clarified. Three predominant interrelated 
mechanisms (the renin- angiotensin system, inflammation 
and oxidative stress) and pathways( TGF-β signaling 
pathways, WNT signaling pathways, MAPK signaling 
pathways) appear to be involved and are used as screening 
principle for categories of AF fibrosis remodeling related 
genes [6-8]. Thus, the categories of AF fibrosis remodeling 
related genes were obtained according to the screening 
principles mentioned above. In our analysis, substantial 
gender differences could be detected in the categories of 
AF fibrosis remodeling related genes (Figure 5A and 5B): 
• female- specific: GO, 16; Pathway1
• overlapping: GO, 12; Pathway, 6
• male-specific: GO, 15; Pathway0
Representative top5 categories of AF-related gene 
are shown as follows: 
GO analysis (Figure 5C): 
• female-specific group: chronic inflammatory 
response; positive regulation of NF-kappaB 
import into nucleus
• overlapping group: Inflammatory response; 
ECM organization; collagen fibril organization
• male-specific group: transforming growth factor 
beta (TGF-β) receptor signaling pathway; ECM 
disassembly 
Pathway analysis (Figure 5D): 
• female-specific group: Renin-angiotensin 
system
• overlapping group: NF-kappa B signaling 
pathway; ECM-receptor interaction; MAPK 
signaling pathway; Toll-like receptor (TLR) 
signaling pathway
male-specific group: TGF-β signaling pathway  
Interesting, our analysis showed that in females, the 
most obvious category was inflammation- related, while 
in males, the most obvious category was ECM- related 
(Figure 5C and 5D) underlining the substantial gender-
specific differences in regard to fibrosis remodeling related 
genes in LSP-AF. 
Gender difference in fibrosis remodeling related 
genes
Of note, the genes obtained from the categories of 
AF fibrosis remodeling related genes are not all involved 
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Figure 5: Gender differences in fibrotic-remodeling-related genes and their categories. A., Comparative analysis of GO 
categories of fibrosis-related genes between female LSP-AF and male LSP-AF group. B., Comparative analysis of Pathway categories of 
AF-related genes between female LSP-AF and male LSP-AF group. Pink, Female-specific part; Purple, overlapping part, Blue, Male-specific 
part. C., GO categories of fibrosis-related genes (Top5) : Female-specific categories (red bar): chronic inflammatory response; positive 
regulation of NF-kappaB import into nucleus; Overlapping categories (red and blue bar): Inflammatory response; ECM organization; 
collagen fibril organization; male-specific categories (blue bar) : transforming growth factor beta (TGF-β) receptor signaling pathway, ECM 
disassembly. Y axis, -log
10
P-value; X axis, GO categories of fibrosis-related genes; D., Pathway categories of fibrosis-related genes(Top5): 
Female-specific categories (red bar):’Renin-angiotensin system; Overlapping categories (red and blue bar): NF-kappa B signaling pathway, 
ECM-receptor interaction, MAPK signaling pathway;Toll-like receptor (TLR) signaling pathway; Male-specific categories (blue bar): 
TGF-β signaling pathway. Y axis, -log
10
P-value; X axis, Pathway categories of fibrosis remodeling related genes. E., Gender differences in 
fibrosis remodeling related genes: Female group fibrosis remodeling related genes: 20 fibrotic remodeling-related genes, with 14 pro-
fibrotic gene (up-regulated gene, 8; down-regulated gene 6) and 6 anti-fibrotic gene (up-regulated, 1; down-regulated,5); Male group 
fibrosis remodeling related genes:16 fibrotic remodeling-related genes, with 15 pro-fibrotic genes (up-regulated, 0; down-regulated, 15) and 
1 anti-fibrotic gene (up-regulated, 0; down-regulated, 1) X axis, number of fibrotic remodeling-related genes; Y axis, categories of fibrosis 
related gene (pro-fibrotic gene and anti-fibrotic gene).red bar, up-regulated pro-fibrotic gene; blue bar, down-regulated pro-fibrotic gene; 
pink bar, up-regulated anti-fibrotic gene; yellow bar, down- regulated anti-fibrotic gene.
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Figure 6: Gender differences in fibrosis remodeling-related proteins (X60, bar = 50 um). A., Gender different expression 
of TGF-β2, COL1A1, COL1A2, COL3A1, SMAD3, INHBA, NR4A1, PARP1, TGF-β1 protein between LSP-AF and NON-AF by 
immunohistochemistry with hematoxylin counter staining. Quantitative assessments of positive area by integrate optical density (IOD) 
of TGF-β2, COL1A1, COL1A2, COL3A1, SMAD3, INHBA, NR4A1, PARP1, TGF-β1between LSP-AF and NON-AF respectively are 
shown b.-J. Female group: NAF (Dot), n = 25; AF (Square), n = 25; Male group: NAF (Triangle), n = 25; AF (Inverted triangle), n = 25. 
PNS > 0.05 between NAF and LAF; P * < 0.05 between NAF and LAF; P ** < 0.01 between NAF and LAF.NAF, NON-AF; LAF, long- 
standing-persistent AF. 
Oncotarget53722www.impactjournals.com/oncotarget
in the regulation of fibrosis remodeling [9]. Therefore, 
in order to clarify the mechanism of gender differences 
in fibrosis remodeling, in our further analysis we only 
selected the genes involved in regulation of fibrosis 
remodeling and the function of each screened gene was 
carefully looked up on PubMed (www.pubmed.com) 
(Supplemental Table 12). 
Our analysis revealed the following results (Figure 
5E): 
Female group: 20 fibrotic remodeling-related genes, 
with 14 pro-fibrotic gene (up-regulated gene, 8; down-
regulated gene 6) and 6 anti-fibrotic gene (up-regulated 
gene, 1; down- regulated, 5). 
Male group: 16 fibrotic remodeling-related genes, 
with 15 pro-fibrotic genes (up-regulated gene, 0; down-
regulated gene, 15) and 1 anti-fibrotic gene (up-regulated 
gene, 0; down- regulated gene, 1).
Interestingly, while both genders were comparable 
in regard to the number of pro-fibrotic genes (females: 14 
and males: 15), the number of up-regulated pro-fibrotic 
genes was substantially higher in females (n = 8), while 
there were no up-regulated genes in males at all.
Immunohistochemistry
In a next step, we further validated our gene 
expression results from microarray on a protein level. 
Eight, randomly selected genes (TGF-β2, SMAD3 [10, 
11],COL1A1, COL1A2, COL1A3 [12],PARP1 [13], 
INHBA [14] and NR4A1 [15] from the categories of 
AF-related genes of the microarray were validated at 
corresponding protein level by immunohistochemistry 
(IHC). IHC analysis showed (Figure 6A) that the 
expression of TGF-β2 (Figure 6B), COL1A2 (Figure 
6D), COL3A1 (Figure 6E), SMAD3 (Figure 6F), PARP1 
(Figure 6I) were significantly higher in the female LSP-
AF group, but not in the male LSP-AF group. In contrast, 
COL1A1 (Figure 6C), INHBA (Figure 6G), NR4A1 
(Figure 6H) did not show significant gender differences in 
the LSP-AF groups. 
Importantly, it is to mention that all significantly 
higher expressed proteins((TGF-β2, SMAD3 [10, 11], 
COL1A2, COL1A3 [12],PARP1 [13] ) are pro-fibrosis-
associated proteins and belong to or regulate the TGF-beta 
signaling pathway, suggesting that the TGF-β pathway 
plays a key role in promoting fibrosis remodeling in the 
female LSP-AF group. To assess this in more detail, in 
a subsequent step, further analysis for TGF-β1, which is 
another key molecule in TGF-β signaling, was performed. 
Notably, it was also found to be significantly higher 
expressed in the female LSP-AF group, but not in the male 
LSP-AF group (Figure 6A and 6J) underlining this theory.
Western blot
Based on our IHC findings and as the TGF-β 
pathway is suggested the classic signaling pathways 
in regulation of fibrotic remodeling [11], Western blot 
analysis was performed. It showed that the expression of 
P-SMAD3/SMAD3 (Figure 7A and 7C), TGF-β2 (Figure 
7A and 7D), TGF-β1 (Figure 7B and 7E), COL1A2 
(Figure 7B and 7F), and COL3A1 (Figure 7B and 7G) 
was significantly up-regulated in the female LSP-AF 
group, but not in the male LSP-AF group, which further 
verified the TGF-β signaling pathway to play an important 
regulatory role in promoting fibrosis remodeling in the 
female LSP-AF group.
DISCUSSION
Significant gender-specific differences in fibrosis 
remodeling in AF patients
In this study, we detected for the first time significant 
mechanistic gender differences in the fibrotic remodeling 
in patients with LSP-AF using a rigorous study design. 
Notably tissue samples from females with LSP-AF, 
rather than male, showed a higher degree of fibrosis than 
samples from patients without AF. Moreover, the degree of 
fibrosis was closely related to LSP-AF and showed better 
predictive values for the presence of LSP-AF in females 
but not in males. Further analysis demonstrated that these 
gender differences in fibrosis remodeling of LSP-AF were 
mainly due to inherent differential expression of fibrosis-
related genes and proteins. Especially those, related to 
the TGFβ/Smad3 pathway, were up-regulated in female 
LSP-AF group suggesting the aggravation of fibrosis 
remodeling.
Comparison with other studies and selection of 
study cohort
Although gender differences in prevalence and 
outcomes were recently reviewed [16], and despite 
significant advancements in the clinical understanding of 
AF in the past decade, to date, only few studies providing 
mechanistic insight into the gender-specific differences 
in fibrosis remodeling and AF are available [17, 18]. For 
instance, in their recent report, Pfannmüller and colleagues 
biochemically assessed tissue samples from 123 patients 
with sinus rhythm (SR, n  =  41) or atrial fibrillation (AF, 
n  =  82) and suffering from mitral valve disease, did not 
detect any significant gender-specific difference in regard 
to fibrotic remodeling [17]. Interestingly, those findings 
differ from ours, and we believe that the reasons for this are 
multifaceted and are mainly attributable to the selection of 
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Figure 7: Gender differences in TGF-β signaling pathway. A. and B., Representative images of Western blot results for P-SMAD3, 
SMAD3, TGF-β2, TGF-β1,COL1A2, COL3A1 (female: non-AF, n = 5;LSP-AF, n = 6; male: non-AF, n = 5;LSP-AF,n = 6;) of pulmonary 
vein sleeves in female / male group with and without AF (GAPDH was used as the loading control). Scatter plots shows a summary and 
comparison of quantitative results of C. P-SMAD3/ SMAD3, D. TGF-β2, E. TGF-β1, F. COL1A2, and (G) COL3A1 were detected 
between NAF and LAF. Female group: NAF (Dot),n = 8; AF (Square) ,n = 9; Male group: NAF (Triangle) , n = 8; AF (Inverted triangle) 
,n = 9.PNS > 0.05 between NAF and LAF; P * < 0.05 between NAF and LAF; P ** < 0.01 between NAF and LAF. NAF, NON-AF; LAF, 
long- standing- persistent AF. 
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our patient cohort and our rigorous study design: First, we 
exclusively included patients with LSP-AF, while previous 
studies did not specifically do this important distinction 
between the types of AF. Secondly, even if the previous 
study had indeed only chosen LSP-AF patients, a biasing 
effect of potential confounders such as mitral valve disease 
and accompanying left atrial enlargement were most 
often not particularly considered and even completely 
neglected. Mitral valve disease is well established to be 
often accompanied by left atrial enlargement [19], which 
is an independent risk factor for fibrosis remodeling and 
AF [20-22]. Therefore, we only enrolled mitral valve 
disease patients with LSP-AF that also presented with left 
atrial enlargement. Finally, in our view, the presence of 
strict controls was critical to determine our main result 
that significant gender differences in fibrosis remodeling 
can be found in patients with LSP-AF. For this reason, we 
took particular care, that also our non-AF control patients 
displayed similar characteristics with LSP-AF  group in 
regards to mitral valve disease, and importantly left atrial 
enlargement, which was not the case in previous [23, 24]. 
In another report, Cochet and colleagues used cardiac 
MRI to show that the degree of atrial fibrosis is higher 
in female AF patients when compared male counterparts 
[18]. However, while the authors in this study primarily 
focused on the gender-specific comparison among AF 
patients, our primary aim was on gender differences in 
fibrosis remodeling between AF and non-AF patients in 
order to highlight that the fibrosis plays a gender-specific 
role in the occurrence and maintenance of AF.
Aggravation of fibrosis remodeling in women as 
a reason for the low success rate of AF ablation?
While the exact mechanism for this phenomenon 
remains to be elucidated, fibrosis has been suggested to 
play a key role in this regard. Fibrosis remodeling leads to 
a dissociation in atrial conduction and thereby promotes 
AF which then ultimately results in a lower efficacy of 
ablation therapy.
Despite being a reasonable treatment strategy for 
AF patients in general, catheter ablation outcomes in 
females are worse when compared to men. [5]. While the 
reason for this is still unclear, the mechanism and degree 
of fibrosis remodeling seems to be a key mediator of this 
gender-specific phenomenon [6] [7]. Our findings clearly 
demonstrated that female LSP-AF, rather than male, 
presented with a higher degree of fibrosis than non-AF 
suggesting that the lower success rates of AF catheter 
ablation observed in women may be attributed to the 
aggravation of fibrosis remodeling in females. Thus, the 
inhibition of fibrosis may increase success rates of AF 
catheter ablation in females and gender-specific anti-
fibrosis treatments may be considered for future therapy 
concepts in women with LSP-AF. 
Gender-specific molecular mechanisms in atrial 
fibrosis of AF patients
Although fibrosis may be considered as an 
interesting therapeutic target in the future, the exact 
gender-specific underlying molecular mechanisms in 
atrial fibrosis of LSP-AF are still extensively debated and 
Figure 8: Gender-difference in remodeling and homeostasis of ECM.
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remain to be elucidated. In this context, our systematic 
analysis using microarray, immunohistochemistry and 
Western Blot may provide useful insight. Remarkably, 
our data indicated that gender differences were not only 
present in fibrosis remodeling-related genes but also in 
fibrosis remodeling related proteins. While the microarray 
results detected 14 pro-fibrotic genes with 8 being up-
regulated in women, it showed 15 pro-fibrotic genes, 
with none being up-regulated in men. In line with these 
findings, IHC and Western Blot analysis further verified 
these findings. With numerous genes (that were randomly 
selected from the microarray analysis; TGF-β2, SMAD3, 
COL1A2, COL1A3, and PARP1) showing a significant 
up-regulation the female LSP-AF group (versus the female 
NON-AF group), while no difference was seen between 
male groups. 
Furthermore, the TGF-β pathway is known to 
be a classic regulatory pathway of fibrosis remodeling 
[11]. Notably, in our Western Blot analysis, we found 
several Pro-fibrosis related proteins (TGF-β1, TGF-β2, 
P-Smad3, COL1A2, and COL1A3) ,which belong to 
TGF-β pathway, that showed gender-specific differences 
between NON-AF and LSP-AF group, with a significant 
up-regulation in the female LSP-AF group, but not in 
the male counterpart. Finally, PARP-1, being involved 
in regulating the TGF-β signaling pathway by promoting 
TGF-β1-induced Smad3 transactivation and expression of 
Smad3 target genes, such as collagen Iα1, collagen IIIα1 
[13, 25] was also significantly up-regulated females, but 
not males with LSP-AF.
Taken together, and based on our analysis we 
hypothesize that in women, but not in men with AF the 
TGF signaling pathway is activated and thereby promotes 
the increased expression of fibrosis-related proteins 
leading to the disturbance of the ECM homeostasis and the 
aggravation of fibrosis remodeling (Figure 8).Therefore, 
inhibition of TGFβ/Smad3 pathway-mediated fibrosis 
could prevent the aggravation of fibrosis remodeling and 
may improve the success rate of AF catheter ablation in 
women .
Limitations
As all patients in our study had LSP-AF, the 
conclusions drawn from this study cannot be applied to a 
population with other types of AF such as lonely AF and 
paroxysmal AF. 
CONCLUSIONS
When compared to men, our study shows a 
significant aggravation of fibrosis remodeling in women 
with LSP-AF which may be a major reason for the overall 
lower success rates of AF catheter ablation in women. As 
demonstrated by our mechanistic analysis targeting TGFβ/
Smad3 pathway-mediated fibrosis could be an interesting 
focus for future therapy concepts in order to improve the 
success rate of AF catheter ablation in females.
MATERIALS AND METHODS
Study subjects
This study was conducted in the department of 
Cardiovascular Surgery of Shenyang North Hospital, 
China. 
A total of 166 patients with dilated left atria and 
concomitant mitral valve disease were enrolled from June 
2015 to May 2016 and divided into four groups by gender 
and AF status (female NON-AF, female LSP-AF, male 
NON-AF, male LSP-AF) (Supplemental Figure7). 
Since AF when associated with mitral valve disease 
is often accompanied by left atrial enlargement [21] 
(which is a well-known independent risk factor for fibrosis 
remodeling and AF [20]), we only included LSP-AF or 
NON-AF patients with a similar degree of atrial dilation 
in order to exclude any experimental bias. The dilated left 
atria were defined according to ESC guidelines as follows 
[26]: male left atrial diameter (LAD) > 40mm, female 
LAD > 38mm. However, since the extent of left atrial 
enlargement is not defined the similar between genders 
[26], we decided to choose the left atrial enlargement ratio 
(left atrial diameter respectively divided by minimum 
threshold of left atrial enlargement in men and women) 
as a screening factor (Table1), in order to eliminate this 
inconsistency. The similarity of left atrial enlargement 
rates between male and female patients was an important 
baseline clinical characteristic for all comparative analyses 
in our study. 
In addition, patients with diabetes and those who 
reported smoking or alcohol consumption within 10 years 
were excluded from the study. Patients’ characteristics 
were listed in the Table1. The enrolled female patients 
were all post -menopausal, thus avoiding any potential 
effect of estrogen. All patients were classified as 
preoperative functional status III according to New York 
Heart Association (NYHA) guidelines. The diagnosis of 
LSP-AF was made according to AHA/ACC/ESC/HRS 
guidelines [27]. The LSP-AF patients had a history of AF 
for 1 year after which a rhythm control strategy is often 
adopted [28]. The NON-AF patients in normal sinus 
rhythm had no history of any type of AF or use of any 
anti-arrhythmic drugs.
Trimmed-off tissues of pulmonary vein sleeves 
(1 cm away from right pulmonary vein orifices) 
(Supplemental Figure8) were obtained from the edge of 
the incisions of left atria during mitral valve surgery +/- 
MAZE III surgery). In 46 of all patients, the size of each 
pulmonary vein sleeve was about 8x4mm-6x4mm (female: 
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NON-AF, n = 11; LSP-AF, n = 12; male: NON-AF, n = 11; 
LSP-AF, n = 12).A portion of the tissue (≈5x4mm) was 
immediately snap-frozen in liquid nitrogen, and stored at 
−80°C, while the other part (≈3x4mm-1x4mm) was fixed 
in neutral formalin. In the remaining 120 patients, a piece 
of pulmonary vein sleeve < 6x4mm (female: NON-AF, n 
= 19; LSP-AF, n = 43; male: NON-AF, n = 24; LSP-AF, 
n = 34) was fixed in neutral formalin. No complications 
occurred as a consequence of tissue sampling.
Ethics approval and informed consent
The Chinese Ethics Committee of Registering 
Clinical Trials approved this study, and the investigation 
complied with the principles for the use of human tissues 
outlined in the Declaration of Helsinki. All patients gave 
informed consent before participating in the study. Ethics 
committee approval No: ChiECRCT-20150025. There was 
no industry involvement in the design or performance of 
the study or in the analysis of the data.
Masson trichrome staining
Paraffin-embedded pulmonary vein sleeve tissue 
samples were sectioned (3 µm) and Masson’s trichrome 
staining (Baso Diagnostics Inc. Zhuhai, China) was 
performed as described elsewhere to evaluate collagen 
(blue color) of pulmonary vein sleeve. After Masson’s 
trichrome staining, the collagen volume fraction 
(CVF) was determined via quantitative morphometry 
using Image-Pro Plus 6.0 under a 60× microscopic 
magnification, which was expressed as the percentage 
of pixels of positive collagen staining divided by total 
pixels of the image (CVF = collagen area/total area). Five 
random images with fibrosis of each section were selected. 
The mean of 5 sections per specimen represented the CVF 
of the assessed pulmonary vein sleeve. 
Immunohistochemistry
Paraffin-embedded pulmonary vein sleeve tissue 
samples were sectioned (3 µm), and subjected to de-
paraffinization, rehydration, and antigen retrieval before 
the staining procedures. The tissue slides were blocked 
with 1% bovine serum albumin for 30 min and then 
incubated with rabbit anti-human TGF-β1, TGF-β2, 
SMAD3, INHBA, NR4A1 (1:100, Proteintech, Chicago, 
USA), COL1A1, COL1A2, COL3A1 (1:100, Santa Cruz 
Biotechnology Inc. CA, USA), and PARP1 (1:100, CST, 
Boston, USA) overnight at 4 °C. Then, antibody binding 
was detected using Horseradish peroxidase-conjugated 
goat anti- rabbit IgG (1:500, Zhongshan Golden Bridge 
Biotechnology Co., Beijing, China) for 1 h at 37 °C and 
then rinsed with water, counterstained with hematoxylin 
and mounted with Neutral balsam. The sections were 
visualized with diaminobenzidine solution, lightly 
counterstained with hematoxylin, and observed using 
light microscopy. Negative control slides were processed 
without primary antibody and were included for each 
staining. All slides were reviewed by 2 pathologists. The 
presence of buffy or brown diaminobenzidine precipitates 
is indicative of positive reactivity. The integral optical 
density (IOD) of immunohistochemical intensity was 
analyzed by Image-Pro Plus 6.0 software. Each value 
represents IOD counted at a high-power view (x60) by 
microscopy. The mean value represents the average 
number derived from five high-power fields of each case. 
RNA extraction
To extract RNA, frozen tissues were ground 
into powder with mortar and pestle and resuspended in 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA 
purification was performed on the RNA-containing 
aqueous phase with the RNeasy minikit (Qiagen, Valencia, 
CA, and USA). RNA was then eluted with RNase-free 
water and treated with turbo DNase (Ambion) to remove 
any contaminating DNA. Quantification and RNA 
quality evaluation were performed with Nanodrop and 
Agilent2100 Bioanalyzer, respectively. A260/A280 in all 
samples was more than 1.8 and there were no degradation 
fragments in electrophoresis images (data not shown).
Microarray analysis
Purified RNA was amplified and transcribed into 
cRNA utilizing a random priming method and cDNA was 
labeled and hybridized to the Gene Chip Human Gene 2.0 
ST Array (Affymetrix). In total, 70,524 transcripts both 
coding and non-coding were covered. Gene Chip Human 
Gene 2.0 ST Array protocol was followed; in brief: Step 1, 
preparation of the RNA sample, kit and reagents (TRIzol 
reagent and miRNeasy Mini Kit). Step 2, total RNA clean-
up and RNA QC. Step 3, preparation of labeling reaction 
and reagents: Gene Chip WT Terminal Labeling and 
Controls Kit. Step 4, purification of the labeled/amplified 
RNA and labeled cRNA QC. Step 5, hybridization. 
Step 6, microarray wash. Step 7, scanning. Step 8; data 
extraction using Affymetrix Extraction Software. The 
arrays were scanned by Gene Chip® Command Console® 
Software (AGCC) and the acquired array images were 
analyzed by Affymetrix Gene Chip Operating Software. 
QC analysis of Gene 2.0 ST Array data was performed 
using the Affymetrix® Expression Console™ Software. 
Differentially expressed genes were selected with the Two 
Class Dif method, and were identified through random 
variance model (RVM) [29]. Heat maps representing 
differentially regulated genes were generated using Cluster 
3.0. The threshold used to screen up- or down-regulated 
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genes was fold-change > 1.2 and P < 0.05. The microarray 
data discussed in this study have been deposited in NCBI’s 
Gene Expression Omnibus and are accessible through 
GEO Series accession number GSE76899 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi? acc = GSE76899).
Gene ontology  and pathway analysis
Gene ontology (GO) and Pathway Analysis were 
applied to classify differentially expressed AF related 
genes. GO is the key functional classification method 
used at NCBI and can organize genes into hierarchical 
categories and uncover gene regulatory networks on the 
basis of biological processes and molecular functions. 
Canonical pathways representing genes were identified 
using the curated IPA (Ingenuity Pathway Analysis) 
database according to KEGG, Biocarta, and Reatome, as 
previously described. Fisher’s exact test and v2 test were 
used for statistical analysis. The threshold of significance 
was defined by the P-value and FDR, and enrichment 
score was expressed in -log 
10
P-value for comparative 
analysis of the categories [30-32]. 
Western blotting
Tissue samples (≈22 mg) were thawed, minced and 
homogenized in lysis buffer with a Dounce homogenizer 
on ice, and centrifuged at 12000 rpm for 20 minutes 
at 4 °C. Supernatants were collected, and the protein 
concentrations were measured with Pierce® BCA Protein 
Assay Kit (Thermo Scientific, Rockford, IL, USA). Equal 
amounts of proteins were separated on SDS gels and 
electro blotted onto polyvinylidene difluoride (PVDF) 
membrane (EMD Millipore, Billerica, USA). Membranes 
were incubated overnight with the following antibodies: 
rabbit anti-human TGF-β1, TGF-β2, SMAD3 (1:1000, 
Proteintech, Chicago, USA), P-SMAD3 (1:1000, CST, 
Boston, USA), COL1A2, COL3A1 (1:1000, Santa Cruz 
Biotechnology Inc. CA, USA).Horseradish peroxidase-
conjugated goat anti- rabbit IgG (1:500, Zhongshan 
Golden Bridge Biotechnology Co., Beijing, China) 
were used as secondary antibodies. Rabbit anti-human 
GAPDH (1:5000, Abcam, Cambridge, UK) was used in 
every experiment for the internal control. Reactive bands 
were developed and enhanced by SuperSignal West Pico 
chemiluminescence detection reagents according to the 
instructions of the manufacturer (Thermo Scientific, 
Rockford, IL, USA), and the images were scanned, 
and densities of each band were analyzed by Total Lab 
software (Nonlinear Dynamics). The results are presented 
as percent change compared with that in controls after 
normalization to the GAPDH bands of each sample.
Statistical analysis
All group data were expressed as the mean ± SEM 
from at least three independent experiments. The chi-
square test was used to determine differences of constituent 
ratio between groups. Student’s unpaired t-test was used to 
determine differences between groups. All P-values were 
two-sided and obtained by using PASW Statistics 18 and 
Graph Pad Prism 5. Statistical significance was considered 
at P < 0.05.
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